Skip to main content

Advertisement

SpringerLink
Log in

Hepatocellular carcinoma: MR staging and therapeutic decisions

  • Published:
Abdominal Imaging Aims and scope Submit manuscript

Abstract

Staging of hepatocellular carcinoma (HCC) represents a controversial and complex topic, since prognosis is largely dependent on several variables other than tumor extension, such liver function and general clinical conditions. Up to now, there is no agreement regarding the most reliable clinical staging system for HCC. Ideally, the staging system should be simple and easily obtainable and should not be influenced by differences in patient populations. So far, in Western countries, the Barcelona Clinic for Liver Cancer (BCLC) staging system represents the most frequently adopted classification. It is simple and guides the clinicians through the therapeutic decision process. Magnetic resonance imaging represents the most proper imaging modality for correct staging of HCC, providing high accuracy in evaluating tumor extension as well as tumor response to treatment (after percutaneous ablation, transarterial chemoembolization, or molecular-targeted therapy). The present review describes the most frequently used staging systems and the treatment options that are recommended for the different stages of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Poon D, Anderson BO, Chen LT, et al. (2009) Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10(11):1111–1118

    Article  PubMed  Google Scholar 

  2. Daniele B, Perrone F (2005) Staging for liver cancer. Clin Liver Dis 9(2):213–223

    Article  PubMed  Google Scholar 

  3. Masuzaki R, Yoshida H, Tateishi R, Omata M (2010) Staging systems: is there a surgical staging and a medical one?: hepatologist’s perspective. J Hepatobiliary Pancreat Surg 17(4):440–442

    Article  Google Scholar 

  4. Contreras CM, Vauthey JN (2010) Staging systems: is there a surgical staging and a medical one? A surgeon’s perspective. J Hepatobiliary Pancreat Surg 17(4):438–439

    Article  Google Scholar 

  5. Dohmen K (2004) Many staging systems for hepatocellular carcinoma: evolution from Child-Pugh, Okuda to SLiDe. J Gastroenterol Hepatol 19(11):1227–1232

    Article  PubMed  Google Scholar 

  6. Kitai S, Kudo M, Minami Y, et al. (2008) Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. Oncology 75(Suppl 1):83–90

    Article  PubMed  Google Scholar 

  7. Yen YH, Changchien CS, Wang JH, et al. (2009) A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Dig Liver Dis 41(6):431–441

    Article  PubMed  Google Scholar 

  8. Luo KZ, Itamoto T, Amano H, et al. (2008) Comparative study of the Japan Integrated Stage (JIS) and modified JIS score as a predictor of survival after hepatectomy for hepatocellular carcinoma. J Gastroenterol 43(5):369–377

    Article  PubMed  CAS  Google Scholar 

  9. Nanashima A, Omagari K, Sumida Y, et al. (2009) Evaluation of new prognostic staging systems (SLiDe score) for hepatocellular carcinoma patients who underwent hepatectomy. Hepatogastroenterology 56(93):1137–1140

    PubMed  Google Scholar 

  10. Hsu CY, Huang YH, Hsia CY, et al. (2010) A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring system. J Hepatol 53(1):108–117

    Article  PubMed  Google Scholar 

  11. Tateishi R, Yoshida H, Shiina S, et al. (2005) Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 54(3):419–425

    Article  PubMed  CAS  Google Scholar 

  12. Vauthey JN, Lauwers GY, Esnaola NF, et al. (2002) Simplified staging for hepatocellular carcinoma. J Clin Oncol 20(6):1527–1536

    Article  PubMed  Google Scholar 

  13. Ramacciato G, Mercantini P, Cautero N, et al. (2005) Prognostic evaluation of the new American Joint Committee on Cancer/International Union Against Cancer staging system for hepatocellular carcinoma: analysis of 112 cirrhotic patients resected for hepatocellular carcinoma. Ann Surg Oncol 12(4):289–297

    Article  PubMed  Google Scholar 

  14. Kee KM, Wang JH, Lee CM, et al. (2007) Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5, 613 cases from a medical center in southern Taiwan. Int J Cancer 120(12):2650–2655

    Article  PubMed  CAS  Google Scholar 

  15. Vauthey JN, Ribero D, Abdalla EK, et al. (2007) Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment. J Am Coll Surg 204(5):1016–1028

    Article  PubMed  Google Scholar 

  16. Lu W, Dong J, Huang Z, et al. (2008) Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI. J Gastroenterol Hepatol 23(12):1874–1878

    Article  PubMed  Google Scholar 

  17. Okuda K, Ohtsuki T, Obata H, et al. (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56(4):918–928

    Article  PubMed  CAS  Google Scholar 

  18. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28(3):751–755

  19. The Cancer of the Liver Italian Program (CLIP) Investigators (2000) Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 31(4):840–845

    Article  Google Scholar 

  20. Farinati F, Rinaldi M, Gianni S, Naccarato R (2000) How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 89(11):2266–2273

    Article  PubMed  CAS  Google Scholar 

  21. Ueno S, Tanabe G, Sako K, et al. (2001) Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology 34(3):529–534

    Article  PubMed  CAS  Google Scholar 

  22. Levy I, Sherman M, Liver Cancer Study Group of the University of Toronto (2002) Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 50(6):881–885

    Article  PubMed  CAS  Google Scholar 

  23. Zhao WH, Ma ZM, Zhou XR, Feng YZ, Fang BS (2002) Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score. World J Gastroenterol 8(2):237–242

    PubMed  Google Scholar 

  24. Hsu CY, Hsia CY, Huang YH, et al. (2010) Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer 116(12):3006–3014

    Article  PubMed  Google Scholar 

  25. Lin CY, Kee KM, Wang JH, et al. (2009) Is the cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. Liver Int 29(1):74–81

    Article  PubMed  Google Scholar 

  26. Marrero JA, Fontana RJ, Barrat A, et al. (2005) Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41(4):707–716

    Article  PubMed  Google Scholar 

  27. Chevret S, Trinchet JC, Mathieu D, et al. (1999) A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire. J Hepatol 31(1):133–141

    Article  PubMed  CAS  Google Scholar 

  28. Schag CC, Heinrich RL, Ganz PA (1984) Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 2(3):187–193

    PubMed  CAS  Google Scholar 

  29. Leung TW, Tang AM, Zee B, et al. (2002) Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 94(6):1760–1769

    Article  PubMed  Google Scholar 

  30. Huitzil-Melendez FD, Capanu M, O’Reilly EM, et al. (2010) Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol 28(17):2889–2895

    Article  PubMed  Google Scholar 

  31. Kudo M, Chung H, Osaki Y (2003) Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 38(3):207–215

    Article  PubMed  Google Scholar 

  32. Kondo K, Chijiiwa K, Nagano M, et al. (2007) Comparison of seven prognostic staging systems in patients who undergo hepatectomy for hepatocellular carcinoma. Hepatogastroenterology 54(77):1534–1538

    PubMed  Google Scholar 

  33. Chung H, Kudo M, Takahashi S, et al. (2008) Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol 23(3):445–452

    Article  PubMed  Google Scholar 

  34. Kudo M (2010) Real practice of hepatocellular carcinoma in Japan: conclusions of the Japan Society of Hepatology 2009 Kobe Congress. Oncology 78(Suppl 1):180–188

    Article  PubMed  Google Scholar 

  35. Llovet JM, Brú C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19(3):329–338

    Article  PubMed  CAS  Google Scholar 

  36. Sørensen JB, Klee M, Palshof T, Hansen HH (1993) Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 67(4):773–775

    Article  PubMed  Google Scholar 

  37. Cheng AL, Kang YK, Chen Z, et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25–34

    Article  PubMed  CAS  Google Scholar 

  38. Llovet JM, Ricci S, Mazzaferro V, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390

    Article  PubMed  CAS  Google Scholar 

  39. Cillo U, Vitale A, Grigoletto F, et al. (2006) Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 44(4):723–731

    Article  PubMed  Google Scholar 

  40. Forner A, Reig ME, de Lope CR, Bruix J (2010) Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 30(1):61–74

    Article  PubMed  CAS  Google Scholar 

  41. Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430

    Article  PubMed  CAS  Google Scholar 

  42. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208–1236

    Article  PubMed  Google Scholar 

  43. Livraghi T, Meloni F, Di Stasi M, et al. (2008) Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 47(1):82–89

    Article  PubMed  Google Scholar 

  44. Mazzaferro V, Regalia E, Doci R, et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 334:693–699

    Article  PubMed  CAS  Google Scholar 

  45. Yao FY, Ferrell L, Bass NM, et al. (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33(6):1394–1403

    Article  PubMed  CAS  Google Scholar 

  46. Mazzaferro V, Llovet JM, Miceli R, et al. (2009) Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 10(1):35–43

    Article  PubMed  Google Scholar 

  47. Yao FY, Kerlan RK Jr, Hirose R, et al. (2008) Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 48(3):819–827

    Article  PubMed  Google Scholar 

  48. Ravaioli M, Grazi GL, Piscaglia F, et al. (2008) Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 8(12):2547–2557

    Article  PubMed  CAS  Google Scholar 

  49. Lewandowski RJ, Kulik LM, Riaz A, et al. (2009) A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 9(8):1920–1928

    Article  PubMed  CAS  Google Scholar 

  50. Otto G, Herber S, Heise M, et al. (2006) Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 12(8):1260–1267

    Article  PubMed  Google Scholar 

  51. Bargellini I, Vignali C, Cioni R, et al. (2010) Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria-selection parameter for liver transplantation. Radiology 255(1):289–300

    Article  PubMed  Google Scholar 

  52. Mazzaferro V, Chun YS, Poon RT, et al. (2008) Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol 15(4):1001–1007

    Article  PubMed  Google Scholar 

  53. Graziadei IW, Sandmueller H, Waldenberger P, et al. (2003) Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 9(6):557–563

    Article  PubMed  Google Scholar 

  54. Liang HH, Chen MS, Peng ZW, et al. (2008) Percutaneous radiofrequency ablation versus repeat hepatectomy for recurrent hepatocellular carcinoma: a retrospective study. Ann Surg Oncol 15(12):3484–3493

    Article  PubMed  Google Scholar 

  55. Massarweh NN, Park JO, Farjah F, et al. (2010) Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg 210:441–448

    Article  PubMed  Google Scholar 

  56. Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M (2009) Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 104(2):514–524

    Article  PubMed  Google Scholar 

  57. Cho YK, Kim JK, Kim MY, Rhim H, Han JK (2009) Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 49(2):453–459

    Article  PubMed  Google Scholar 

  58. Livraghi T, Giorgio A, Marin G, et al. (1995) Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 197(1):101–108

    PubMed  CAS  Google Scholar 

  59. Sala M, Llovet JM, Vilana R, et al. (2004) Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 40(6):1352–1360

    Article  PubMed  Google Scholar 

  60. Lencioni R, Cioni D, Crocetti L, et al. (2005) Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 234(3):961–967

    Article  PubMed  Google Scholar 

  61. Lencioni R, Crocetti L, Petruzzi P, et al. (2008) Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. J Hepatol 49(2):217–222

    Article  PubMed  CAS  Google Scholar 

  62. Llovet JM, Fuster J, Bruix J (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30(6):1434–1440

    Article  PubMed  CAS  Google Scholar 

  63. Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP (2003) Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 197:753–758

    Article  PubMed  Google Scholar 

  64. Llovet JM, Beaugrand M (2003) Hepatocellular carcinoma: present status and future prospects. J Hepatol 38(Suppl 1):S136–S149

    Article  PubMed  Google Scholar 

  65. Yang B, Zou J, Xia J, et al. (2010) Risk factors for recurrence of small hepatocellular carcinoma after long-term follow-up of percutaneous radiofrequency ablation. Eur J Radiol [Epub ahead of print]

  66. Lo CM, Ngan H, Tso WK, et al. (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171

    Article  PubMed  CAS  Google Scholar 

  67. Llovet JM, Real MI, Montaña X, et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739

    Article  PubMed  Google Scholar 

  68. Lammer J, Malagari K, Vogl T, et al. (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V Study. Cardiovasc Intervent Radiol 33:41–52

    Article  PubMed  Google Scholar 

  69. Sangro B, Salem R, Kennedy A, Coldwell D, Wasan H (2010) Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol Jul 8 [Epub ahead of print]

  70. D’Avola D, Lñarrairaegui M, Bilbao JI, et al. (2009) A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. Hepatogastroenterology 56(96):1683–1688

    PubMed  Google Scholar 

  71. Iñarrairaegui M, Thurston KG, Bilbao JI, et al. (2010) Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 21(8):1205–1212

    Article  PubMed  Google Scholar 

  72. Salem R, Lewandowski RJ, Mulcahy MF, et al. (2010) Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138(1):52–64

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diagnostic and Interventional Radiology, Pisa University Hospital, Via Paradisa 2, 56124, Pisa, Italy

    Irene Bargellini

Authors
  1. Irene Bargellini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Irene Bargellini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bargellini, I. Hepatocellular carcinoma: MR staging and therapeutic decisions. Abdom Imaging 37, 231–238 (2012). https://doi.org/10.1007/s00261-011-9735-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-011-9735-8

Keywords

Search

Navigation